Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
boston top stories
4
×
crispr
4
×
life sciences
national blog main
gene editing
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
clinical study
commissioner
democrats
detroit blog main
detroit top stories
editas medicine
failure
fda
glaxosmithkline
ipo
katrine bosley
medical devices
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
scott gottlieb
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2025
ad-comm
What
crispr
4
×
bio
big
cas
ceo
editas
katrine
medicine
million
roundup
allergan
allogene
available
based
biosciences
blessing
bosley
bosley's
bosley’s
bridge
bucks
cancer
cheaper
check
clinical
crime
cusp
depart
departure
develop
diagnostics
diversity
editing
exit
expects
experimental
faster
gene
guiding
hot
Language
unset
Current search:
crispr
×
biotech
×
crispr
×
" boston top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More